Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Horizon Pharma

Biotech giant Amgen Inc. ( AMGN , Financial) is on a mission to meet unmet medical needs while generating solid returns for investors. As part of this strategy, the company has recently been taking advantage of lower stock valuations to make attractive buyout offers for biotech players with promising treatments.

Horizon Jumps 15% on $26 Billion Acquisition Deal

At 3.5 Years, 83% of Patients on BLINCYTO Plus Chemotherapy Were Alive Versus 65% of Patients on Chemotherapy Alone Trial Design and Conduct Sponsored by the ECOG-ACRIN Cancer Research Group THOUSAND OAKS, Calif. , Dec. 13, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present results from the E1910 randomized Phase 3 trial.

BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)

Risk reversal option trades combine a short out-of-the-money put and a long out-of-the-money call. Here's how it works.

How A Bullish Risk Reversal Option Trade Works On Amgen Stock

First Trust Nasdaq Pharmaceuticals ETF 

iShares U.S. Pharmaceuticals ETF

Invesco Dynamic Pharmaceuticals ETF

VanEck Vectors Pharmaceutical ETF

SPDR S&P Pharmaceuticals ETF

Amgen (AMGN) has agreed to buy Horizon Therapeutics PLC (HZNP) for $27.8 billion. This put the spotlight on pharma ETFs, which could be the best way for investors to tap the opportunity arising from the proposed deal.

Amgen to Buy Horizon Therapeutics: ETFs to Bet On

Chevron

Merck

Travelers

Here we have shortlisted five stocks - CVX, MRK, AMGN, TRV and IBM- that have fared better than the Dow Jones Index this year and have more upside potential for investment consideration.

5 Dow Stocks That Helped the Index Minimize Loss in 2022

Amgen has become the winner in the Horizon Therapeutics sale process. The deal comes at a full price, offset by synergy estimates and pipeline additions.

Amgen: 'Winner' For Horizon

THOUSAND OAKS, Calif. , Dec. 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the first quarter of 2023.

AMGEN ANNOUNCES 10% INCREASE IN 2023 FIRST QUARTER DIVIDEND

NEW YORK , Dec. 12, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Horizon Therapeutics Public Limited Company ("Horizon Therapeutics" or the "Company") (NASDAQ: HZNP) in connection with the proposed acquisition of the Company by Amgen Inc. (NASDAQ: AMGN).  Under the terms of the merger agreement, the Company's shareholders will receive $116.50 in cash for each share of Horizon Therapeutics common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Horizon Therapeutics Public Limited Company

Mirati Therapeutics

Mirati won FDA approval for its rival to Amgen's lung cancer drug on Monday. The approval comes as MRTX stock continues to experience wild swings.

Mirati Wins FDA Approval For Amgen-Rivaling Cancer Drug As Wild Stock Swing Continues

The purchase of Horizon Therapeutics is the biggest this year by a major drugmaker seeking new sources of revenue to offset impending patent expiries.

Amgen Hunts for New Revenue in $28 Billion Deal

Amgen Inc. said Monday that it's acquiring Dublin-based Horizon Therapeutics in a roughly $28 billion deal that is the biggest in the healthcare sector in 2022.

Amgen wins battle for Horizon Therapeutics, bolstering its rare-disease portfolio

Horizon is the largest disclosed holding of John Paulson's family office Paulson & Co., according to Forbes.

Billionaire John Paulson is reportedly set to reap $500 million from Amgen's huge deal to acquire Horizon Therapeutics

Amgen is acquiring Horizon Therapeutics for $27.8 billion. The deal immediately adds $3.7 billion in annual revenue.

Horizon Therapeutics Acquisition: A Good Deal For Amgen Investors

Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.

Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion

Amgen Inc. will acquire Horizon Therapeutics Public Limited Company for $116.50 per share in an all-cash transaction. This is a suboptimal exit for Horizon shareholders, but we should acknowledge the difficult market conditions.

What Amgen Is Getting Through The Acquisition Of Horizon Therapeutics

Sales of Horizon's thyroid-eye disease drug Tepezza have plateaued, a challenge its new owner will need to contend with.

First Test for Amgen: Fix Horizon's Growth Problem

Coupa Software

Consensus is currently for a 50 basis point (bps) hike mid-week, which will bring the Fed funds rate over +4% for the first time in 15 years.

Busy Week Highlighted by Next Fed Rate Move

Hedge fund billionaire John Paulson stands to reap about $500 million if Amgen's deal for Horizon goes through. It's the latest victory for the man who shot to fame for his big bet during the subprime crisis.

Billionaire John Paulson Stands To Make $500 Million From Horizon's Sale To Amgen

Amgen's planned acquisition of Horizon could close in the first half of next year.

Why Horizon Therapeutics Stock Is Soaring Today

Amgen Inc. announced on Monday that it will acquire Horizon Therapeutics for $26 billion to further grow the company's medical legacy. Horizon's best-selling drug is Tepezza.

Amgen to buy Horizon Therapeutics for $26.4B

Horizon Therapeutics (NASDAQ: HZNP ) stock is up 15% today on news that pharmaceutical giant Amgen (NASDAQ: AMGN ) will acquire the Ireland-based company for $27.8 billion. The acquisition of Horizon Therapeutics is one of the biggest deals in the healthcare space this year, according to industry data.

Horizon Therapeutics (HZNP) Stock Pops on HUGE Amgen Deal

The shares of Horizon Therapeutics PLC (NASDAQ:HZNP) are up 14.9% at $111.75 this morning, following reports that Amgen (AMGN) will buy the biopharmaceutical company in a deal worth roughly $26.4 billion.

$26.4 Billion Amgen Buyout Sends Horizon Stock Soaring

Amgen announced a $28.3 billion plan to acquire Horizon Therapeutics on Monday, leading HZNP stock to soar higher. The post Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal appeared first on Investor's Business Daily.

Amgen To Buy Rare Diseases Drugmaker Horizon Therapeutics In $28.3 Billion Deal

Amgen reaches a deal to buy drug company Horizon Therapeutics for $116.50 a share in cash.

Amgen to Buy Horizon Therapeutics

US biotechnology giant Amgen, Inc confirmed weekend speculation that it will be acquiring Horizon Therapeutics by formally unveiling a US$26.4bn swoop for the rare diseases drug maker. This will be the most significant transaction in Amgen's history and will give the company access to Horizon's blockbuster drug, Tepezza, which is used to treat thyroid eye disease.

News for Amgen Stock (AMGN)